Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

Table 1 Patient’s neo-epitopes to which T cell reactivity was detected.

Patient	% Tumor	# Mut	# SLP	# SSP	Genes	Mut cDNA	Mut a.a.	% Mut (WES)	Peptide	Peptide ID
NIC3	21	21	24	47	PARVA	c.328C>G	p.P110R	11	NLPLSPIPFELDREDTMLEENEVRT	L01
					G3BP1	c.244G>A	p.A82T	11	NCHTKIRHVDAHTTLNDGVVVQVMG	L13
					G3BP1	c.244G>A	p.A82T	11	IRHVDAHTTL	S13-1
NIC4	48	30	39	46	ACTR10	c.638G>A	p.R213H	15	SVPEGVLEDIKAHTCFVSDLKRGLK	L06
					RAE1	c.1106A>G	p.X369W	13	WWLETLAQPELFLSTLPHLCTNLGP	L20-2
					PDP1	c.1024C>T	p.R342W	45	PKSEAKSVVKQDWLLGLLMPFRAFG	L29
					PDP1	c.1024C>T	p.R342W	45	SEAKSVVKQDW	S29-1
					PDP1	c.1024C>T	p.R342W	45	SEAKSVVKQDWL	S29-2
NIC5	72	49	71	94	–	–	–	–	–	–
NIC6	79	23	24	32	–	–	–	–	–	–
NIC7	78	33	44	70	–	–	–	–	–	–
NIC15	43	15	15	108	QRICH1	c.1054C>A	p.V352F	14	VHVSGSPTALAAFKLEDDKEKMVGT	L11
NIC17	51	45	47	60	–	–	–	–	–	–

% Tumor tumor purity, Mut mutation, SLP synthetic long peptides, SSP synthetic short peptides, WES reads in whole-exome sequencing.

ISSN: 1756-994X